Healthcare makes India business stronger
GE Healthcare Life
Sciences provides cutting-edge technology products and processes
to pharma, biopharma and biotechnology companies and major
academic and research institutions globally.
Headquartered in the UK, GE Healthcare is a
$17-billion unit of General Electric, one of the world’s
largest diversified conglomerates. Worldwide, GE Healthcare employs
more than 46,000 and its products are used in about 100 countries. The
company’s India business recorded revenue of Rs 120 crore for
the year ending March 2008-09.
GE Healthcare works in the primary areas of healthcare systems
(diagnostic imaging and clinical systems), medical diagnostics,
surgery, healthcare IT solutions and life sciences. Over the years, the
company has significantly increased its focus on its life sciences
business in India, driven largely by the growth in the domestic
biotechnology sector. Last year, it substantially increased its
commercial footprint and service capabilities in India to cater to the
customers’ needs faster and more efficiently.
GE Healthcare Life Sciences has been a key supplier of
bioprocess, protein purification, chromatography, columns, media and
filtration needs to the major players in India in the biotech space and
GE’s products and services are generally regarded
by customers as the best-in-class. With around 30 years of experience
in biopharmaceuticals, their products and solutions are generally
considered to be the gold standard in biopharmaceutical production.
Anurag Gupta, managing director, GE Healthcare Life Sciences claims,
“About 95 percent of around 120 FDA-approved
biopharmaceuticals are manufactured using GE Healthcare Life
Sciences’ products. This level of proven leadership is
important everywhere and is valued by companies in India.”
GE Healthcare Life Sciences has a service team and commercial
team in India with offices at Bangalore, Delhi, Chennai,
Mumbai, Hyderabad, Kolkata, Lucknow, Pune and Chandigarh.
GE Healthcare Life Sciences has introduced a new portfolio of
ready-to-use systems and devices designed for biopharmaceutical
production. The ReadyToProcess portfolio is a range of
products designed to meet the biopharmaceutical industry’s
need for increased speed, simplicity and safety for all areas of
bioprocessing—from cell culture and fermentation to final
GE Healthcare Life Sciences recently acquired MicroCal, a
provider of innovative instruments for the study of molecular
interactions in pharmaceutical, biomedical and life science research.
MicroCal’s proprietary technology, which is complementary to
GE Healthcare’s Biacore platform, provides scientists with
detailed information across several stages of the drug discovery
process, reducing the potential for late-stage drug candidate